Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849901 · ClinicalTrials.gov registry record · Phase 3
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 337
- Enrollment target
NCT00849901 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 337 participants.
The verdict
NCT00849901, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 337 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
Interventions
- DRUG Placebo
- DRUG duloxetine
- DRUG fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00849901
The ClinicalTrials.gov registry entry for NCT00849901 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00849901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00849901 about?
NCT00849901 is a clinical study titled "A Study in the Treatment of Children and Adolescents With Major Depressive Disorder". The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
What is the current status of trial NCT00849901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 337 participants. The study started on 2009-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00849901?
The interventions under investigation include: Placebo (DRUG), duloxetine (DRUG), fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00849901?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.